Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial Meeting Abstract
| Authors: | Picozzi, V. J.; Varghese, A. M.; Oberstein, P. E.; Hidalgo, M.; Wolpin, B. M.; Lim, K. H.; McGlothlin, A.; Graves, T.; Detry, M. A.; Fitzgerald, M.; Bosse, A.; Moravek, C.; Pedersen, S.; Berkenblit, A.; Chen, J.; Carrier, E.; Adib, D. R.; Berry, D. A.; Simeone, D. M.; Ko, A. H. |
| Abstract Title: | Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial |
| Meeting Title: | 2025 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2025 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-01 |
| DOI: | 10.1200/JCO.2025.43.4_suppl.673 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting Abstract: 673 -- Source: CINAHL Plus with Full Text |
